Table 2: Incidence of adverse events.

VPZ group ()PPI group () value VPZ versus PPIRPZ group () value VPZ versus RPZ

Overall19 (26.3%)26 (37.7%)0.150520 (33.9%)0.3497
Loose stool12 (16.6%)12 (17.4%)0.90899 (15.3%)0.8265
Diarrhea6 (8.3%)10 (14.5%)0.24908 (13.6%)0.3354
Dysgeusia3 (4.1%)6 (8.7%)0.31925 (8.5%)0.4664
Skin eruption1 (1.4%)3 (4.3%)0.35912 (3.4%)0.5881
Abdominal bloating1 (1.4%)2 (2.9%)0.61431 (1.7%)1.0000
Epigastralgia0 (0%)2 (2.9%)0.23772 (3.4%)0.4504
Constipation1 (1.4%)1 (1.4%)1.00001 (1.7%)1.0000
Nausea1 (1.4%)1 (1.4%)1.00001 (1.7%)1.0000
Others2 (2.8%)4 (5.8%)0.43483 (5.1%)0.6571

Data are expressed as number (percentage). Statistical analyses were conducted with the chi-square test or Fisher’s exact test. VPZ group, treatment with vonoprazan, amoxicillin, and clarithromycin; PPI group, treatment with rabeprazole or lansoprazole, amoxicillin, and clarithromycin; RPZ group, treatment with rabeprazole, amoxicillin, and clarithromycin.